Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the factors that might increase the risk of breast cancer coming back in women who have locally advanced breast cancer and have received chemotherapy before surgery, a treatment known as neoadjuvant chemotherapy. Researchers want to understand why some patients experience early disease recurrence (EDR), which means the cancer returns within three years after treatment. They are particularly interested in using advanced imaging techniques, like MRI, to help predict which patients may be more likely to face this challenge.

To participate in this trial, women over 18 years old with specific types of locally advanced breast cancer (including triple-negative and HER2-positive) that have undergone neoadjuvant chemotherapy between January 2014 and June 2021 may be eligible. Participants will have their clinical data and MRI images analyzed to help improve understanding of cancer recurrence. This research aims to provide better predictions for future patients and ultimately improve treatment outcomes for women facing breast cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of locally advanced Luminal or HER2+ or Triple-negative breast cancer (cT2, T3, T4 N0 or any T N1, N2, N3, M0), clinical stage of disease from I to III.
• • Patient undergoing neoadjuvant chemotherapy treatment from January 1, 2014, to June 30, 2021.
• • Age \> 18 years
• • Availability of clinical data, staging MRI diagnostic images (for the radiomic sub-study), and biomolecular data.
• Exclusion Criteria:
• • Previous or synchronous history of systemic malignancies.
• • History of ipsilateral or contralateral breast neoplasia.
• • Evidence of metastatic disease (Stage IV).
• • Neoadjuvant treatment with hormone therapy.
• • Patients with unavailable or low-quality MRI images that did not allow lesion identification (for the radiomic study only).